|1.||Yoo, Byung Chul: 9 articles (07/2014 - 07/2004)|
|2.||Byun, Kwan Soo: 7 articles (07/2014 - 05/2006)|
|3.||Lee, Hyo-Suk: 7 articles (01/2012 - 07/2004)|
|4.||Alauddin, Mian M: 6 articles (11/2013 - 04/2002)|
|5.||Paik, Seung Woon: 6 articles (03/2013 - 05/2006)|
|6.||Kim, Ju Hyun: 6 articles (01/2013 - 05/2007)|
|7.||Yoo, Hee-Won: 5 articles (03/2011 - 05/2006)|
|8.||Han, Joon-Yeol: 5 articles (03/2011 - 05/2006)|
|9.||Lee, Kwan Sik: 5 articles (03/2011 - 01/2007)|
|10.||Yoo, Kwon: 5 articles (03/2011 - 05/2006)|
|1.||Chronic Hepatitis B
12/01/2010 - "clevudine is a potent antiviral agent that has demonstrated efficacy in patients with chronic hepatitis B. "
01/01/2010 - "The objectives of this study were to evaluate the safety and efficacy of a 1-year treatment with clevudine in chronic hepatitis B patients. "
12/01/2010 - "Efficacy of initial treatment with clevudine in naive patients with chronic hepatitis B."
09/01/2009 - "[Efficacy of 48-week clevudine therapy for chronic hepatitis B]."
04/01/2013 - "The aim of this study was to investigate antiviral effects and adverse events of clevudine monotherapy in patients with chronic hepatitis B (CHB). "
06/01/2010 - "Hepatitis B was reactivated with a flare-up, and a M204I mutation (YIDD mutant type) appeared with a higher viral load at 9 months after clevudine treatment. "
06/01/2010 - "Clevudine (30 mg once daily) was administered for recurrent hepatitis B. "
05/01/2009 - "Clevudine for hepatitis B."
06/01/2008 - "To characterize pharmacokinetic and pharmacodynamic profile of clevudine, a potent hepatitis B polymerase inhibitor. "
06/01/2009 - "Seven hepatitis B patients who developed severe skeletal myopathy during clevudine therapy were examined in this study. "
11/01/2013 - "After tumor size reached 150 ± 50 mm(3) (day 0), lipo-VNB (5mg/kg) was intravenously administered on days 0, 3 and 6. To monitor the therapeutic efficacy of lipo-VNB, [(18)F]FMAU PET was employed to evaluate the proliferation rate of tumor, and it was compared with that observed from [(18)F]FDG/[(18)F]fluoroacetate PET. "
11/01/2013 - "Previous studies have shown that the accumulation level of FMAU in tumor is proportional to its proliferation rate. "
05/01/2004 - "We performed pharmacokinetic measurements with [(14)C]FMAU and PET studies with [(11)C]FMAU using rats bearing several different syngeneic tumors. "
01/01/1985 - "We have conducted a phase I trial of FMAU in 17 patients with advanced cancer. "
11/01/2013 - "[(18)F]FMAU PET is an appropriate modality for early monitoring of the tumor response during the treatment course of lipo-VNB."
|4.||Muscular Diseases (Myopathy)
02/01/2011 - "The aim of this study was to evaluate antiviral efficacy, predictors of virologic response, and development of myopathy after clevudine therapy for CHB. "
08/01/2010 - "The aim of this study was to define the clinical, biochemical, and pathological characteristics of myopathy developed during clevudine therapy. "
06/01/2009 - "Our study was aimed to analyze the clinical and pathological features of patients with clevudine-induced myopathy with some consideration of its pathogenetic mechanism. "
07/01/2014 - "However, long-term treatment with clevudine monotherapy induced resistance and myopathy in some cases. "
04/01/2013 - "Fluctuations in CK level during the clevudine treatment period were frequently observed irrespective of development of myopathy. "
|5.||Sarcoma (Soft Tissue Sarcoma)
11/01/2013 - "Monitoring tumor response with [18F]FMAU in a sarcoma-bearing mouse model after liposomal vinorelbine treatment."
11/01/2013 - "This study demonstrated that 2'-deoxy-2'-[(18)F]fluoro-β-d-arabinofuranosyluracil ([(18)F]FMAU) is a promising PET probe for noninvasively monitoring the therapeutic efficacy of 6% PEGylated liposomal vinorelbine (lipo-VNB) in a subcutaneous murine NG4TL4 sarcoma mouse model. "
|3.||Hepatitis B e Antigens
|8.||Antiviral Agents (Antivirals)
|9.||Arabinofuranosyluracil (Ara U)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)